A Phase II, Single-arm, Open-labeled Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC

Trial Profile

A Phase II, Single-arm, Open-labeled Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms RESCUE
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 15 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top